Best of Targeted Therapies of Lung Cancer (TTLC) 2026 Enduring-Recording

Video Transcription

Video Summary

This ISLC “Best of TTLC 2026” webinar, moderated by Drs. Luis Reyes and Deborah Doroshow, reviewed key TTLC updates in targeted therapy, immunotherapy, and small cell lung cancer (SCLC).<br /><br />Dr. Melinda Hsu summarized major targeted-therapy themes: the evolving KRAS mutation landscape; KRAS G12C inhibitor strategies (including combination approaches and the challenge of hepatotoxicity with some ICI combinations); and how KRAS co-mutations (e.g., STK11, KEAP1, TP53 and others) may influence prognosis and response, with mixed evidence across datasets but signals that certain co-mutations predict poorer outcomes. She also reviewed emerging KRAS G12D inhibitors showing encouraging early response rates with generally manageable toxicity, and provided an EGFR exon 20 update, highlighting newer agents (e.g., sunvozertinib and others) that may offer activity—sometimes even after prior amivantamab—with toxicity profiles that appear improved versus amivantamab.<br /><br />Dr. Tiziana Leal reviewed immunotherapy duration in metastatic NSCLC, supporting two years of ICI as current standard, noting real-world data suggesting no OS disadvantage versus indefinite therapy and less toxicity. She discussed de-escalation trials (stop at 6 months, lower dose, longer intervals) and emerging combination/bispecific approaches.<br /><br />Dr. Paul Bunn covered new SCLC directions: chemo-ICI standards, DLL3-targeted bispecifics (notably tarlatamab) with durable benefit in a subset but early-cycle CRS/ICANS risks, plus growing roles for lurbinectedin combinations, ADCs (e.g., CEACAM5/TROP2/B7-H3-related programs), and VEGF/PD-1 bispecifics. A panel discussion addressed practical stopping decisions, biomarkers, and feasibility as these therapies move earlier in care.

Keywords

TTLC 2026 webinar

targeted therapy NSCLC

KRAS G12C inhibitors

KRAS co-mutations STK11 KEAP1 TP53

KRAS G12D inhibitors

EGFR exon 20 inhibitors

immunotherapy duration 2 years

small cell lung cancer SCLC

DLL3 bispecific tarlatamab CRS ICANS